Effect of Recombinant Human Thrombopoietin in the Treatment of Septic-related Thrombocytopenia

Thrombocytopenia is prevalent in patients with severe sepsis, and it is associated with mortalities. So it’s clinical significant to early intervene in the thrombocytopenia?in patients with sepsis. Recombinant human thrombopoietin (rhTPO) functions as endogenous platelet hormone, stimulating the growth and differentiation of megakaryocytes in the marrow, and eventually splitting into mature peripheral blood platelets. In recent years rhTPO has been gradually used to treat platelet reduction caused by severe sepsis, for its good tolerability and good effect in increasing the platelet counts.